You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK):治療肌萎縮性脊髓側索硬化症新藥上市申請獲藥監局受理
格隆匯 02-06 18:59

格隆匯2月6日丨李氏大藥廠(00950.HK)公告,於2019年12月30日,公司全資附屬公司李氏大藥廠(香港)有限公司的《Teglutik》®新藥上市申請已獲中國國家藥品監督管理局受理,該藥物乃用於治療肌萎縮性脊髓側索硬化症。

《Teglutik》®為ItalfarmacoS.A.引進產品,Italfarmaco為一家專業製藥公司,於五大洲60多個國家從事探索、開發、製造及營銷品牌處方藥及非處方藥。於2019年11月26日與Italfarmaco簽署分銷協議後,李氏香港獲授獨家分銷權,以在中國、香港、澳門及台灣開發及商業化《Teglutik》®。

此外,公司董事會欣然宣佈,新增《菲普利》®每盒四瓶裝的包裝規格將於2020年第一季度推出,或會成為該品牌於未來數年的新增長動力,這是基於Italfarmaco授予的《菲普利》®獨家分銷權經考慮到Italfarmaco與李氏香港訂立的長期分銷安排讓《菲普利》®於中國市場取得持續增長而已於2019年8月獲延續。根據經重續的安排,該產品的銷售地區亦將涵蓋香港、澳門及台灣。通過集團新成立的OTC藥品銷售團隊,該新增規格《菲普利》®將有利集團建立更多銷售網絡及覆蓋更大範圍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account